Figure 2 | Modern Pathology

Figure 2

From: Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinicopathologic parameters and biomarkers

Figure 2

ER, PR(total), PR-B and Her-2/neu. (a–c) ER (alpha): nuclear expression. (a) No ER expression in endometrial carcinoma (negative) ( × 40). (b) ER expression in carcinoma-associated complex atypical hyperplasia, 2+ positive ( × 40). (c) ER expression in carcinoma-associated normal endometrium, 3+ positive ( × 400). (d–f) PR (total): nuclear expression. (d) No PR expression in endometrial carcinoma (negative) ( × 40). (e) PR expression in carcinoma-associated complex atypical hyperplasia, 3+ positive ( × 40). (f) PR expression in carcinoma-associated normal endometrium, 3+ positive ( × 400). (g–i) PR-B: nuclear and cytoplasmic expression. (g) No PR-B expression in endometrial carcinoma (negative) ( × 40). (h) PR-B expression in carcinoma-associated complex atypical hyperplasia, 3+ positive, predominantly nuclear expression ( × 40). (i) PR-B expression in carcinoma-associated normal endometrium, 2+ positive, cytoplasmic expression (arrow head) ( × 400). (j–k) Her 2/neu protein overexpression: cell membrane pattern. (j) Her 2/neu overexpression in endometrial carcinoma, 3+ ( × 400). (k) Her 2/neu overexpression in carcinoma-associated complex atypical hyperplasia, 2+ ( × 200). (l) No Her 2/neu overexpression in carcinoma-associated normal endometrium, (0) ( × 200). CA=endometrial carcinoma.

Back to article page